surmount-1 trial tirzepatide weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide and blood pressure reduction:

One strength of this study was that it broke down the median weight loss after 1 year by peak dosage, which shows us that a higher dosage of injectable semaglutide was more efficacious overall than a smaller dose of tirzepatide

The injection is delivered using a pre-filled, single-dose pen designed for easy at-home use

This is why the exact unit calculation for your dose is not just academic

Your provider will determine which option is most appropriate for your medical profile and goals

Temporary soreness during rapid weight loss is a metabolic adaptation, not tissue damage, and resolves once hydration and protein intake improve

What is a Tirzepatide Injection